Cargando…

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Fulbert, Kano, Jessica, Ma, Julia, Guindy, Mera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946878/ https://www.ncbi.nlm.nih.gov/pubmed/35323345 http://dx.doi.org/10.3390/curroncol29030145

Ejemplares similares

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
por: Royer, Bernard, et al.
Publicado: (2021)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
por: Lee, Jieun, et al.
Publicado: (2021)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy
por: Bui, Tam Binh V, et al.
Publicado: (2019)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
por: Mo, Hongnan, et al.
Publicado: (2022)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
por: DeMichele, Angela, et al.
Publicado: (2023)

Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary
por: Babcock, Aram, et al.
Publicado: (2020)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
por: Shao, Xiying, et al.
Publicado: (2021)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
por: Mycock, Katie, et al.
Publicado: (2021)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
por: Sawaki, Masataka, et al.
Publicado: (2023)

RENATA study—Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer—real-world use
por: Petracci, Fernando, et al.
Publicado: (2020)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)
por: Low, Jia Li, et al.
Publicado: (2022)

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study
por: Beachler, Daniel C., et al.
Publicado: (2021)

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
por: Kish, J. K., et al.
Publicado: (2018)

Erratum: RENATA study—Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer—real-world use
por: Petracci, Fernando, et al.
Publicado: (2020)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
por: Gyanchandani, Rekha, et al.
Publicado: (2016)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario
por: Orbaugh,1, Kristi, et al.
Publicado: (2016)

A single institution experience with palbociclib toxicity requiring dose modifications
por: Gong, Jun, et al.
Publicado: (2017)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
por: Zheng, Jenny, et al.
Publicado: (2020)

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
por: Palumbo, Raffaella, et al.
Publicado: (2021)

Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
por: Cardoso Borges, Fábio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3k14ih360ats5ihh86la76dkk